After declining revenue and profitability for the past several quarters, Divi’s Laboratories (Divi’s) has reported some sign of recovery in Q4FY22-23 sequentially. In Q4FY22-23, although sales declined by 23% y-o-y (year-on-year), sequentially, they rose by 14% to Rs1,951 crore, driven by healthy growth in the generic segment.